1 week Ago By Defense World Staff
Prudential Financial Inc. decreased its stake in shares of Caribou Biosciences, Inc. ( NASDAQ:CRBU – Free Report ) by 84.
2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 20,772 shares of the company’s stock after selling 111,100 shares during the period. Prudential Financial Inc.
’s holdings in Caribou Biosciences were worth $33,000 as of its most recent filing with the SEC. A number of other institutional investors have also made changes to their positions in CRBU. US Bancorp DE raised its position in shares of Caribou Biosciences by 3,524.
2% in the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after purchasing an additional 26,467 shares during the period. Thrive Wealth Management LLC acquired a new position in Caribou Biosciences in the 4th quarter valued at $51,000.
Intech Investment Management LLC raised its holdings in Caribou Biosciences by 69.4% in the 4th quarter. Intech Investment Management LLC now owns 37,478 shares of the company’s stock worth $60,000 after acquiring an additional 15,352 shares during the period.
Sei Investments Co. acquired a new position in Caribou Biosciences during the 4th quarter worth $102,000. Finally, American Century Companies Inc.
boosted its holdings in Caribou Biosciences by 9.2% during the fourth quarter. American Century Companies Inc.
now owns 159,822 shares of the company’s stock valued at $254,000 after acquiring an additional 13,421 shares during the period. 77.51% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth Several research firms recently weighed in on CRBU. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research report on Wednesday, March 19th.
Bank of America cut their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th.
Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $10.33.
Caribou Biosciences Stock Up 1.7 % CRBU stock opened at $0.87 on Friday.
The business’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.61.
The company has a market cap of $81.31 million, a PE ratio of -0.53 and a beta of 2.
36. Caribou Biosciences, Inc. has a twelve month low of $0.
66 and a twelve month high of $4.39. Caribou Biosciences ( NASDAQ:CRBU – Get Free Report ) last released its quarterly earnings data on Monday, March 10th.
The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.
01. The business had revenue of $2.08 million for the quarter, compared to analysts’ expectations of $2.
11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.
81%. On average, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.
64 EPS for the current year. Caribou Biosciences Company Profile ( Free Report ) Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Stories Five stocks we like better than Caribou Biosciences What Are Treasury Bonds? JPMorgan is a Buy, if You Can Handle The Volatility What is Put Option Volume? United States Steel’s Crash: An Unmissable Buying Opportunity Insider Trading – What You Need to Know Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding CRBU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caribou Biosciences, Inc. ( NASDAQ:CRBU – Free Report ).
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
